MHC/KO Mouse Model Development Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized cancer treatment, particularly for hematologic malignancies. However, translating CAR-T cell therapies from bench to bedside encompasses challenges, particularly when predicting human responses during the preclinical stages. Creative Biolabs has developed an advanced MHC knockout (MHC/KO) mouse model to streamline the evaluation of CAR-T therapies and mitigate these obstacles, offering a robust platform for ensuring safety and efficacy.

Features of the MHC/KO Mouse Model

The MHC/KO mouse model incorporates several key features that make it an indispensable tool for CAR-T cell therapy evaluation:

MHC Knockout: By knocking out the Major Histocompatibility Complex (MHC) in these mice, which creates an environment that better mimics the human response to CAR-T cells. This reduces the incidence of murine-specific immune reactions that can confound data, providing clearer insight into human-specific outcomes.
Reduction of GVHD: With the MHC knockout configuration, the risk of Graft-Versus-Host Disease (GVHD) is significantly minimized. This reduction enhances the overall safety profile and extends the experiment window, allowing researchers to monitor long-term CAR-T cell effects.
Extended Observation Period: The reduced risk of GVHD not only ensures the safety and ethical compliance of experiments but also enables extended observation periods. This is crucial for assessing the durability and long-term efficacy of CAR-T treatments.

Potential Applications of the MHC/KO Mouse Model

Utilizing the MHC/KO mouse model opens up a plethora of applications, strengthening the preclinical characterization of CAR-T therapies:

Preclinical Safety Evaluation

Enable detailed studies on cytokine release syndrome (CRS) and other toxicities, ensuring that potential side effects are well understood before clinical trials.

Efficacy Assessment

Measure the therapeutic potential of CAR-T cells against tumor models, quantifying parameters like tumor growth inhibition and overall survival.

Mechanism of Action Studies

Enable deep dives into CAR-T cell behavior and interaction within biological systems, providing insights into mechanisms underlying therapeutic effects and side effects.

Our MHC/KO Mouse Model for CAR-T In Vivo Testing

At Creative Biolabs, we use the MHC/KO mouse model to evaluate the intricacies of CAR-T cell therapies in a controlled and precise manner:

Humanized Immune Context: These mice are humanized with pre-characterized adult Peripheral Blood Mononuclear Cells (PBMCs), which makes them highly suitable for evaluating human immune responses. This is crucial for comprehending the toxicity, efficacy, and overall safety profile of CAR-T therapies.
Toxicity and Efficacy Simultaneously: Our setup allows for concurrent evaluation of both the therapeutic effectiveness and potential adverse effects, as we monitor body weight, temperature, and cytokine levels. Furthermore, tissue samples can be analyzed post-experiment for detailed toxicity profiling.
Tumor Engraftment Capability: The ability to accept tumor engraftments allows researchers to simulate real cancer scenarios, enhancing the translational value of the data collected.

Frequently Asked Questions

Q1: How does the MHC knockout reduce the risk of GVHD?

A1: By knocking out MHC, we minimize murine-specific immune responses that would not be representative of human reactions, thus reducing the instance of GVHD and allowing for extended and safer preclinical trials.

Q2: Can this model be used for solid tumor studies?

A2: Yes, the flexible nature of the MHC/KO mouse model makes it suitable for both hematologic and solid tumor CAR-T cell evaluations. The tumor engraftment capability further enhances its application range.

Partner with Us

Creative Biolabs brings over two decades of expertise in developing innovative preclinical models, leading to enhanced drug discovery and development processes:

Technological Innovation: Combining genetic modification techniques with advanced humanization protocols.
Comprehensive Support: From initial design to final data analysis, we offer end-to-end support for your CAR-T therapy research.
Proven Track Record: Our models have consistently yielded high-quality data, accelerating the path from preclinical research to clinical application.

By choosing Creative Biolabs, you are set to navigate through the complexities of CAR-T therapy development with confidence and efficiency. Contact us today to advance your cell therapy research and development.